Li-San Wang, Ph.D. - US grants
Affiliations: | 2003 | University of Texas at Austin, Austin, Texas, U.S.A. | |
| 2003- | Pathology and Laboratory Medicine | University of Pennsylvania, Philadelphia, PA, United States |
Area:
bioinformaticsWebsite:
http://tesla.pcbi.upenn.edu/~lswang/We are testing a new system for linking grants to scientists.
The funding information displayed below comes from the NIH Research Portfolio Online Reporting Tools and the NSF Award Database.The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please sign in and mark grants as correct or incorrect matches.
High-probability grants
According to our matching algorithm, Li-San Wang is the likely recipient of the following grants.| Years | Recipients | Code | Title / Keywords | Matching score |
|---|---|---|---|---|
| 2012 — 2016 | Wang, Li-San | R01Activity Code Description: To support a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies. |
Computational Genome-Wide Rna Profiling Using Next-Generation Sequencing @ University of Pennsylvania DESCRIPTION (provided by applicant): Recent evidence has shown that non-coding RNAs are ubiquitous in the cell and that their functions and structure vary to a greater extent than previously imagined. Multiple new RNA classes have been implicated in many diseases, and understanding how these RNAs work is a critical need. While exciting discoveries are accumulating, our functional knowledge of these new RNAs remains limited. Here we propose to couple a new high-throughput RNA duplex sequencing technology with new, computational methods to economically study novel functional non-coding RNA at a genomic scale. We propose to develop two computational methodologies to characterize putative newly found non-coding RNAs on the genomic scale. First, we will develop a maximum likelihood approach that estimates RNA secondary structure using RNA-seq assays that preferentially sequence single- or double-stranded nucleotides. Second, we will develop a machine-learning framework that predicts the functional category of novel non-coding RNAs using length and structure features of known RNAs. These structural and functional predictions will be validated by comparative genomics and experimentation. We will develop databases and analysis software, and investigate the human genome and five other model organisms. In total, our findings will yield tremendous insights into non-coding RNA biology and will substantially impact continued study of these important molecules. |
1 |
| 2012 — 2020 | Wang, Li-San | U24Activity Code Description: To support research projects contributing to improvement of the capability of resources to serve biomedical research. |
The Nia Genetics of Alzheimer's Disease Data Storage Site @ University of Pennsylvania DESCRIPTION (provided by applicant): Recent technological advances in genome-wide SNP genotyping and resequencing are revolutionizing how disease research is conducted. New discoveries in AD genetics and the large influx of data present opportunities and challenge to sharing data and integrating knowledge. We propose to enhance the NIA Genetics of Alzheimer's Disease Storage Site (NIAGADS) to support the community to address these challenges, and become a nexus for research in AD genetics and genomics. The new NIAGADS will be governed by researchers in AD genetics, genomics, and bioinformatics with deep understanding of the priorities and needs by the latest science, and supported by a team with expertise in these fields. The NIAGADS data repository will be expanded to accommodate for next generation sequencing data, larger data submissions, and more requests. Simultaneously, we will enhance the repository through developing and sharing workflows for data analysis, and curate commonly used secondary data such as SNP imputation and annotation. We will develop an integrated genomics database to interlink analysis results with genomic annotations, pathways, and genetic variations from publication databases for easy access. Finally, we will develop collaborative initiatives with major AD genetics resources sponsored by NIA, and will actively promote the database through website, publications, and presentations at major conferences. |
1 |
| 2016 — 2020 | Wang, Li-San | U54Activity Code Description: To support any part of the full range of research and development from very basic to clinical; may involve ancillary supportive activities such as protracted patient care necessary to the primary research or R&D effort. The spectrum of activities comprises a multidisciplinary attack on a specific disease entity or biomedical problem area. These differ from program project in that they are usually developed in response to an announcement of the programmatic needs of an Institute or Division and subsequently receive continuous attention from its staff. Centers may also serve as regional or national resources for special research purposes, with funding component staff helping to identify appropriate priority needs. |
Core B - Data Management, Harmonization, and Data Transfer Core @ University of Pennsylvania Core B (Data Management, Harmonization, and Information Transfer) is mandated by RFA-AG-16001 as part of the NIA Coordinating Center for Genetics and Genomics of Alzheimer's Disease (CGAD). Core B's primary goal is to facilitate the analysis of the Replication Phase and Extended Replication Phase of the Alzheimer's Disease Sequence Project (ADSP) by harmonizing all Alzheimer's disease (AD) relevant genotype and phenotype data. The Replication Phase will use ADSP data and the Extended Replication Phase will use non- ADSP data (Core A, Tables 3-5), and data for both phases will be harmonized by Core B. Harmonization will use protocols developed by the ADSP and re-evaluated by Core C. Core B will produce fully annotated analysis-ready files. These files/data will be distributed to Core C and all ADSP/RFA-AG16002 UO1 and AD genetics investigators. Core C will develop and implement analyses plans, in collaboration with other ADSP/RFA-AG16002 UO1 investigators (also see the Overall Component). Core B will provide the high- performance computing infrastructure for computationally intensive tasks. Core B will manage all CGAD phenotype, genotype, annotation, and analysis results, and distribute data/files to all ADSP/RFA-AG16002 investigators, to Genotypes and Phenotypes (dbGaP), and to NIA Genetics of Alzheimer's Data Storage Site (NIAGADS). Specific tasks of Core B are: 1) Capture and maintain all relevant data including sequence data, genotypes, phenotypes, analysis results, and other relevant data from ADSP Discovery Phase, Replication Phase, and non-ADSP sources; 2) Harmonize genotype and phenotype data using protocols in collaboration with Core C; 3) Impute single nucleotide variants (SNVs) for all genome-wide SNV array data using the Haplotype Reference Consortium (HRC) reference panels and AD-specific variants from ADSP WES/WGS data; 4) Call structural variants (SVs) for ADSP Replication and non-ADSP data; 5) Provide in silico annotation analysis-ready files using the Genome Wide Annotation Resource (GWAR) and current ADSP protocols; 6) Transfer information to ADSP, RFA-AG-16002 U01, and the general research community via CGAD/ADSP website, relational databases, and NIA approved data repositories including dbGaP and NIAGADS; 7) Provide infrastructure and support for CGAD computing and analyses. |
1 |
| 2016 — 2020 | Schellenberg, Gerard David [⬀] Wang, Li-San |
U54Activity Code Description: To support any part of the full range of research and development from very basic to clinical; may involve ancillary supportive activities such as protracted patient care necessary to the primary research or R&D effort. The spectrum of activities comprises a multidisciplinary attack on a specific disease entity or biomedical problem area. These differ from program project in that they are usually developed in response to an announcement of the programmatic needs of an Institute or Division and subsequently receive continuous attention from its staff. Centers may also serve as regional or national resources for special research purposes, with funding component staff helping to identify appropriate priority needs. |
Coordinating Center For Genetics and Genomics of Alzheimer's Disease (Cgad) @ University of Pennsylvania ? DESCRIPTION (provided by applicant): The goal of Alzheimer's disease (AD) genetics research is to identify genetic variants that cause, influence risk, or protect against this disordr, and to identify the underlying genes affected by these variants. These genes are then potential therapeutic targets. The goal of the NIA Coordinating Center for Genetics and Genomics of Alzheimer's Disease (CGAD, this application) is to facilitate AD gene discovery by coordinating analysis of all AD-relevant data. As mandated by RFA AG16001, there are 3 cores and an Overall Component. The mandated cores are: 1) Administrative (Core A); 2) Data Management, Harmonization, and Information Transfer Core (Core B); and 3) Biostatistics and Data Analysis Core (Core C). As mandated by RFA AG16001, CGAD will assemble all data (Cores A and B) generated by the Alzheimer's Disease Sequence Project (ADSP) from both the Discovery Phase and the Replication Phase, and all data from non-ADSP sources (Core A) including that generated by grants funded under RFA AG16002. CGAD will; 1) create and support a collaborative network of all CGAD, ADSP, RFA AG16002, and other AD genetics investigators (Core A); 2) harmonize all genetic and phenotype data and fully annotate all variants (Core B); 2) design all harmonization and annotation protocols (Core C, implemented by Core B); 3) design analysis protocols for all data (Core C); 4) implement analyses plans (Core C, except for computationally intensive protocols that will be executed by Core B); 5) broadly distribute primary data, harmonized annotated analysis-ready files, and analyses results including depositing appropriate data into qualified access databases [National Institute on Aging Genetics of Alzheimer's Disease Storage site (NIAGADS) and database of Genotypes and Phenotypes (dbGaP)] (Core B). As mandated by RFA AG16001, all harmonization protocols and analyses plans will be refined in collaboration with all ADSP, RFA AG16002, and other AD genetics investigators. The Overall Component describes in detail the proposed activities and analyses to be executed by the cores. We will analyze Replication Phase data using single and gene-based analyses. Both single nucleotide variants (SNVs) and structural variants (SVs) will be analyzed. We will perform a combined analysis of Replication and Discovery Phase data. We will also perform an Extended Replication Phase using non- ADSP data. We will analyze data from all phases in a pathway network analysis, an interaction analysis, and a polygenic risk score. These gene-discovery activities will lead to potential targets for developing therapeutics. |
1 |
| 2017 | Schellenberg, Gerard David [⬀] Wang, Li-San |
U54Activity Code Description: To support any part of the full range of research and development from very basic to clinical; may involve ancillary supportive activities such as protracted patient care necessary to the primary research or R&D effort. The spectrum of activities comprises a multidisciplinary attack on a specific disease entity or biomedical problem area. These differ from program project in that they are usually developed in response to an announcement of the programmatic needs of an Institute or Division and subsequently receive continuous attention from its staff. Centers may also serve as regional or national resources for special research purposes, with funding component staff helping to identify appropriate priority needs. |
@ University of Pennsylvania |
1 |
| 2017 | Schellenberg, Gerard David [⬀] Wang, Li-San |
U54Activity Code Description: To support any part of the full range of research and development from very basic to clinical; may involve ancillary supportive activities such as protracted patient care necessary to the primary research or R&D effort. The spectrum of activities comprises a multidisciplinary attack on a specific disease entity or biomedical problem area. These differ from program project in that they are usually developed in response to an announcement of the programmatic needs of an Institute or Division and subsequently receive continuous attention from its staff. Centers may also serve as regional or national resources for special research purposes, with funding component staff helping to identify appropriate priority needs. |
@ University of Pennsylvania |
1 |
| 2017 | Schellenberg, Gerard David [⬀] Wang, Li-San |
U54Activity Code Description: To support any part of the full range of research and development from very basic to clinical; may involve ancillary supportive activities such as protracted patient care necessary to the primary research or R&D effort. The spectrum of activities comprises a multidisciplinary attack on a specific disease entity or biomedical problem area. These differ from program project in that they are usually developed in response to an announcement of the programmatic needs of an Institute or Division and subsequently receive continuous attention from its staff. Centers may also serve as regional or national resources for special research purposes, with funding component staff helping to identify appropriate priority needs. |
@ University of Pennsylvania |
1 |
| 2017 | Schellenberg, Gerard David [⬀] Wang, Li-San |
U54Activity Code Description: To support any part of the full range of research and development from very basic to clinical; may involve ancillary supportive activities such as protracted patient care necessary to the primary research or R&D effort. The spectrum of activities comprises a multidisciplinary attack on a specific disease entity or biomedical problem area. These differ from program project in that they are usually developed in response to an announcement of the programmatic needs of an Institute or Division and subsequently receive continuous attention from its staff. Centers may also serve as regional or national resources for special research purposes, with funding component staff helping to identify appropriate priority needs. |
@ University of Pennsylvania |
1 |
| 2017 — 2021 | Dickson, Dennis William (co-PI) [⬀] Geschwind, Daniel H [⬀] Schellenberg, Gerard David (co-PI) [⬀] Steen, Judith A. Wang, Li-San |
UG3Activity Code Description: As part of a bi-phasic approach to funding exploratory and/or developmental research, the UG3 provides support for the first phase of the award. This activity code is used in lieu of the UH2 activity code when larger budgets and/or project periods are required to establish feasibility for the project. UH3Activity Code Description: The UH3 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the UH2 mechanism. Although only UH2 awardees are generally eligible to apply for UH3 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under UH2. |
Impact of Coding and Non-Coding Variation in Progressive Supranuclear Palsy @ University of California Los Angeles Progressive supranuclear palsy (PSP) is the most common frontotemporal lobar degeneration associated with tau pathology. While rare pathogenic variants, common risk factors, and ? more recently ? rare risk-associated variants have been identified in PSP, a significant proportion of the heritability for neurodegenerative tauopathies and other frontotemporal lobar degenerations remains unexplained, strongly suggesting that additional genetic risk factors await discovery. In this application, we propose to identify novel genetic variation associated with PSP using a multi-stage strategy. First, we will detect variants through whole-genome sequencing of neuropathologically characterized PSP. Second, we will prioritize pathological brain tissue samples for a multidimensional screen that includes transcriptional, proteomics, and epigenetic assays. Through recursive application of a prioritization algorithm, regions and variants most likely to have a high impact on disease risk will be identified. Finally, we will follow up on these variants using a high-throughput functional screen. This project taps unprecedented pathologic resources of PSP, leverages a pathologic and genetic infrastructure created with support from private foundations, and offers to transform our understanding of the genetic architecture of PSP and to advance towards the biology and downstream effects of this prototypical tauopathy downstream effects of this prototypical tauopathy. |
0.951 |
| 2021 | Schellenberg, Gerard David [⬀] Wang, Li-San |
U54Activity Code Description: To support any part of the full range of research and development from very basic to clinical; may involve ancillary supportive activities such as protracted patient care necessary to the primary research or R&D effort. The spectrum of activities comprises a multidisciplinary attack on a specific disease entity or biomedical problem area. These differ from program project in that they are usually developed in response to an announcement of the programmatic needs of an Institute or Division and subsequently receive continuous attention from its staff. Centers may also serve as regional or national resources for special research purposes, with funding component staff helping to identify appropriate priority needs. |
Genome Center For Alzheimer's Disease (Gcad) @ University of Pennsylvania Overall Project Summary Alzheimer?s disease (AD) affects 5.8 million people in the United States, and is an immense burden on patients, caregivers and on the economy. No disease-modifying treatments or preventions exist, and we need better understanding of the disease and new therapeutic strategies. Genetic discoveries are one source of candidate therapeutic targets. One source of genetic targets is the Alzheimer?s Disease Sequencing Project (ADSP), a National Institute on Aging (NIA) initiative since 2012 to sequence genomes and exomes of AD subjects and cognitively normal elderly controls. The Genome Center for Alzheimer?s Disease (GCAD) is the analysis coordinating center for the ADSP. In the previous grant cycle, GCAD processed all AD-relevant sequencing data producing harmonized genetic data for AD research. This renewal responds to the increase in the amount and complexity of ADSP sequence data, the collection of new types of data, and an expansion of the types of analysis being performed. In addition to sequence data, GCAD will harmonize functional genomics data. GCAD will provide fully quality-controlled and annotated genetic and functional genomics data that is analysis ready. In addition to AD, GCAD will also work with data for AD related disorders (ADRD). These include frontotemporal dementias (FTDs), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), Lewy body dementia (LBD), and Parkinson?s disease with dementia (PD-d). In the Y6-10 funding period, GCAD will assemble and harmonize whole-genome/whole-exome sequencing data, and provide it to ADSP investigators and the general scientific community. GCAD will work with US and non-US groups to analyze data by fostering a collaborative environment, and providing infrastructure support. GCAD will also assemble and harmonize functional genomics data which will be integral to identifying genes as candidate drug targets. The research plan will lead to a high quality, comprehensive, harmonized collection of genetic and functional data with detailed supporting resources including documentation and optimized computer codes. This resource will be invaluable for the entire AD research community. |
1 |
| 2021 | Wang, Li-San | U54Activity Code Description: To support any part of the full range of research and development from very basic to clinical; may involve ancillary supportive activities such as protracted patient care necessary to the primary research or R&D effort. The spectrum of activities comprises a multidisciplinary attack on a specific disease entity or biomedical problem area. These differ from program project in that they are usually developed in response to an announcement of the programmatic needs of an Institute or Division and subsequently receive continuous attention from its staff. Centers may also serve as regional or national resources for special research purposes, with funding component staff helping to identify appropriate priority needs. |
Core B-Data Management, Harmonization, and Information Transfer Core @ University of Pennsylvania Core B Project Summary Core B (Data Management, Harmonization, and Information Transfer Core) is responsible for facilitating analysis of Alzheimer?s Disease Sequence Project (ADSP) data and other relevant projects by processing and harmonizing all relevant genetic and functional genomics (FG) data. Core B will manage all phenotype, genotype, annotation, and analysis results, and distribute data/files to all ADSP investigators and to NIA Genetics of Alzheimer?s Data Storage Site (NIAGADS), the NIA-designated qualified access repository for AD genetics research. Specific Aims are: (1) Receive and manage all relevant genotypic, phenotypic, and functional genomic data; (2) Calling SNVs, indels and structural variants (SVs) from sequencing data; (3) Develop a GCAD haplotype reference panel with GCAD WGS data for GWAS imputation; (4) Facilitate harmonization of FG/omics data by developing best practices for data processing and coordinate harmonization of ADSP FG Program and other relevant omics data; (5) Support GCAD information technology needs and information dissemination activities. |
1 |
| 2021 | Chui, Helena Chang Jun, Gyungah Park, Van My Ta Wang, Li-San |
R56Activity Code Description: To provide limited interim research support based on the merit of a pending R01 application while applicant gathers additional data to revise a new or competing renewal application. This grant will underwrite highly meritorious applications that if given the opportunity to revise their application could meet IC recommended standards and would be missed opportunities if not funded. Interim funded ends when the applicant succeeds in obtaining an R01 or other competing award built on the R56 grant. These awards are not renewable. |
Asian Cohort For Alzheimer's Disease (Acad) @ University of Pennsylvania Project Summary Alzheimer's disease (AD) affects 5.8 million people in the United States and is an immense burden on our economy, patients and caregivers. Genome-wide association studies (GWAS) have successfully led to 25 genome-wide significant loci associated with AD risk and many more associations with key clinical covariates. Most of these findings are made on participants with European ancestry, although efforts to study other minority populations are taking off. Knowledge about AD genetics among Asian Americans is especially limited due to lack of participants. Comprising 6% of the US populace, Asian Americans are under-sampled and deserve more scientific investment. We propose the Asian Cohort for Alzheimer's Disease (ACAD), the first large Alzheimer's Disease (AD) genetics cohort for Asians in United States (US) and Canada. To optimize ACAD's success, we assembled a team of scientists, clinicians, and community partners with collaborative history and expertise in AD research, human genetics, and Asian community outreach. We propose to recruit 5,970 participants aged 60 years or older and of Chinese, Korean, and Vietnamese ancestry from metropolitan areas across the US and Canada in collaboration with community partners, clinics, or nursing homes that serve Asian communities. We will collect saliva for DNA and use validated, localized instruments, data forms, and clinical/diagnostic protocols. To support these recruitment and data collection activities, we will set up a coordinating center and develop governance, community outreach and training programs to support recruitment and analysis activities, and conduct a process evaluation of the recruitment and outreach efforts. All samples will be genotyped using SNP arrays and imputed using a large Asian-specific reference panel of whole genome sequencing data from international Asian cohorts. We will analyze genetic and clinical data to investigate impact of lifestyle risk factors, genetic variants for AD risk, evaluate differential effects of sex and APOE genotypes on AD risk, and predict clinical diagnosis of AD using genetic and lifestyle risk scores. We will replicate these findings through meta-analysis collaborations with international Asian cohorts and AD studies from other populations. Comprising 6% of the US populace, Asian Americans are under-sampled and deserve more scientific investment in Alzheimer's disease research. The ACAD project will build the first major AD genetics study for Asians in the US and Canada. Successful completion will lead to new genetic and lifestyle screening markers for Asian Americans and insights about novel therapeutic targets for AD. ACAD will be a first network for recruiting and studying AD in Asian Americans that will extend to Asian Indians, Filipino and other Asian American populations in the future, serving the unmet needs of Alzheimer's disease research for Asian Americans. |
1 |